Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-12-28
2009-11-03
Matthews, William H (Department: 3774)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S195110
Reexamination Certificate
active
07612034
ABSTRACT:
A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).
REFERENCES:
patent: 5175146 (1992-12-01), Basava et al.
patent: 5776923 (1998-07-01), Labrie
patent: 5817650 (1998-10-01), McGuire et al.
patent: 5912014 (1999-06-01), Stern et al.
patent: 7045513 (2006-05-01), Parasrampuria et al.
patent: WO 98/23274 (1998-06-01), None
patent: WO 9835704 (1998-08-01), None
patent: WO 00/54763 (2000-09-01), None
Alam, AS, et al. “Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating intracellular Ca2+ mobilization and cell retraction.”J EndocrinolJan. 1993, 136 (1) p7-15.
Avioli, Louis V. “Calcitonin therapy in osteoporotic syndromes”Rheumatic Disease Clinics of North America. vol. 20 No. 3, 1994, pp. 777-785.
Ballica, R. et al.,J. Bone Miner. Res. 14(7):1067 (1999).
Barry et al., (1998) “Dehydroepiandrosterone in Systemic Lupus Erythematosus: Relationship Between Dosage, Serum Levels, and Clinical Response,”The Journal of Rheumatology, 25:12, pp. 2352-2356.
Bird, C.E. et al.,J. Clin. Endocrinol Metab. 47(4):818 (1978).
Borm, A.K.,Horm. Metab. Res. 31(8):472 (1999).
Boross et al., (1983) “Effects of prolonged aminoglutethimid and dehydroepiandrosterone treatment on rat bones,” 9Akt. Gerontol. 13; 15-18.
Boulanger, Y. et al.,Int J. Pept. Protein Res. 47(6):477 (1996).
Bracci-Laudiero L, Aloe L, Lundeberg T, Theodorsson E, Stenfors C. (1999) “Altered levels of neuropeptides characterize the brain of lupus prone mice.”Neurosci Lett. 275(1):57-60. Abstract.
Brunelli MP, Einhorn TA. (1998) “Medical management of osteoporosis. Fracture prevention.”Clin Orthop.(348):15-21. Abstract.
Buckley, L.M. et al.,J. Rheumatol. 24:1489-94 (1997).
Cardona, J.M. et al.,Osteoporos Int. 7(3):165 (1997).
Cerovsky, V. et al.,Eur. J. Biochem. 247(1):231 (1997).
Cornish, J. et al.,Am. J. Physiol. 275(4Pt1):E694.
Cornish, J. et al.,Biochem Biophys. Res. Commun. 207(1):133 (1995).
Downs, R.W. et al.,J. Bone Mineral Res. Suppl. 1, p. S401 (Abstract)(1999).
Epand, R.M. et al.,Int. J. Pept. Protein Res. 27(5):501 (1986).
Fisher, J.A. et al. “Calcitonin Gen Produkte und das Skelett.”Z Orthop Ihre GrenzgebMay- Jun. 1990, 128 (3) p240-2.
Formiga F, Moga I, Nolla JM, Navarro MA, Bonnin R, Roig-Escofet D. (1997) “The association of dehydroepiandrosterone sulphate levels with bone mineral density in systemic lupus erythematosus.”Clin Exp Rheumatol. 15(4):387-92. Abstract.
Hakala, J.M. et al.,Protein Eng. 9(2):143 (1996).
Heinz, D. et al.,Steroids Lip Res. 5(4):216 (1974).
Hizmetli S, Elden H, Kaptanoglu E, Nacitarhan V, Kocagil S. (1998) “The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis.”Int J Clin Pract. 52(7):453-5. Abstract.
Hollo et al., (1971) “Effect of norandrostenolone-decanoate on calcium tolerance curbes of patients with primary osteoporosis,”Endokrinologie, Band 58, Heft 3, S. 326-330.
Jablonski, G. et al.,Calcif. Tissue Int. 57(5):385 (1995).
Kanis, J.A. et al.,J. Bone Mineral Res. 9:1137-1141 (1994).
Katahira, R. et al.,Int. J. Pept. Protein Res. 45(5):305 (1995).
Laan, R.F. et al.,Ann. Int. Med. 119(10):963 (1993).
Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez JL, Candas B. (1998) “DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging.”Steroids. 63(5-6):322-8. Abstract.
Labrie, F. et al.,Ann. N.Y. Acad. Sci. 774:16-28 (1995).
Labrie, F. et al.,J. Clin. Endocrinol. Metab. 82(8):2403 (1997).
Labrie, F.,Mol. Cell Endocrinol. 78:C113-C118 (1991).
Looker, AG. et al.,J. Bone Miner Res. 10(5):796-802 (1995).
Mease, P.J. et al. “GL701 (prasterone, dehydroepiandrosterone) improves bone density in steroid-treated female lupus patients”Journal of Bone and Mineral Research, vol. 15, No. Suppl. 1. Sep. 2000, p. S548 Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research; Toronto, Ontario, Canada; Sep. 22-26, 2000.
Morfin, R. et al.,J. Steroid Biochem. Mol. Biol. 50 (1-2):91 (1994).
Peichl P. et al. “Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.”Gynecol Endocrinol(England) Feb. 1999, 13 (1) p. 7-14.
Perez-Jaraiz MD, Revilla M, Alvarez de los Heros JI, Villa LF, Rico H. (1996) “Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass.”Maturitas. 23(3):327-32. Abstract.
Pietschmann, P. et al. “Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria.”Bone, Mar.-Apr. 1993, 14 (2) p. 167-72.
Pozvek, G. et al.,Mol. Pharmacol. 51(4):658 (1997).
Pucci, E. et al. “Osteoporosis in male hypogonadism synergical activity of androgens and calcitonin” European Journal of Clinical Investigation, Vol. 21, No. 2 Part 2, 1991, p. 28. Abstract.
RF van Vollenhoven (1999) “A double-bind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.”Lupus8, 181-187.
Romero, D.F. et al.,Calcif. Tissue Int.56(1):54 (1995).
Rosen, C.J. et al.J. Bone Mineral Res. 14 supp 1, p. S400 (Abstract)(1999).
Shiraki M : Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA, US; 1987: “The Mechanisms of Bone Mineral Loss with aging Detection of Pathological and physiological loss of bone mineral using single photon absorptiometry” Database accession No. PREV198885065028Abstractand Japanese Journal of Geriatrics, vol. 24, No. 2, 1987, pp. 122-127.
Singer, F.,“ Clinical efficacy of salmon calcitonin in Paget's disease of bone.”Calcif Tissue Int. (US) 1991, 49 Suppl 2, p. 87-88.
Stroop, S.D. et al.,Endocrinology137(11):4752 (1996).
Suva, L.J. et al.,J. Pharmacol. Exp. Ther. 283(2):876 (1997).
Szucs et al., (1992) “Three-year Calcitonin Combination Therapy for Postmenopausal Osteoporosis with Crush Fractures of the Spine,”Calcif. Tissue, 50:7-10.
Thamsborg, G. “Effect of nasal salmon calcitonin on calcium and bone metabolism.”Dan Med Bull(Denmark) Apr. 1999, 46 (2) p. 118-126.
Uda, K. et al. “Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions,” Biol Pharm Bull (Japan) Mar. 1999, 22 (3) p. 244-252,.
Van Staa, T.P. et al.,Bone23(5) supp. S202 (Abstract)(1998).
Van Vollenhoven RF, McGuire JL. (1996) “Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.”Ann Med Interne(Paris). 147(4):290-6. Abstract.
Vignery, A. et al.,Bone18(4):331 (1996).
Watson RR, Huls A, Araghinikuam M, Chung S. (1996) “Dehydroepiandrosterone and diseases of aging.”Drugs Aging. 9(4):274-91. Abstract.
Who Technical Report Series 843 “Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis” Geneva, World Health Organization (1994).
Wild RA, Buchanan JR, Myers C, Demers LM. (1987) “Declining adrenal androgens: an association with bone loss in aging women.”Proc Soc Exp Biol Med. 186(3):355-60. Abstract.
Wimalawansa, S.J. et al.,Crit. Rev. Neurobiol. 11(2-3):167-239 (1997).
Young, J. et al.,J. Clin. Endocrinol. Metab. 82:2578-2585 (1997).
Zaidi M. et al. “The calcitonin gene peptides: biology and clinical relevance.” Crit Rev Clin Lab Sci 1990, 28 (2) p. 109-174.
Genelabs Technologies, Inc.
Matthews William H
Thomas Robert (Steve)
LandOfFree
Treatment of subnormal bone mineral density does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of subnormal bone mineral density, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of subnormal bone mineral density will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4073637